Dynavax

The first round of Covid-19 vaccines is ‘highly unlikely to be a magic bullet,’ Medicago CEO says
The first round of Covid-19 vaccines is ‘highly unlikely to be a magic bullet,’ Medicago CEO says
Stat
Medicago
GSK
Dynavax
vaccines
COVID-19
Flag link:
Using GSK and Dynavax tech, Clover kick-starts COVID-19 vax trial with data drop in August
Using GSK and Dynavax tech, Clover kick-starts COVID-19 vax trial with data drop in August
Fierce Biotech
GSK
Dynavax
Clover BioPharmaceuticals
vaccines
COVID-19
Flag link:
Asthma Drug Co-Developed by Dynavax and AstraZeneca Fails to Meet Endpoints in Phase IIa Trial
Asthma Drug Co-Developed by Dynavax and AstraZeneca Fails to Meet Endpoints in Phase IIa Trial
BioSpace
asthma
Dynavax
AstraZeneca
clinical trials
AZD1419
Flag link:
Watch These Biotechs and the FDA Calendar
Watch These Biotechs and the FDA Calendar
TheStreet.com
FDA
biotech
Dynavax
HEPLISAV-B
Progenics
Azedra
Neurocrine
Elagolix
AbbVie
Flag link:
Watch These February Biotech Catalysts
Watch These February Biotech Catalysts
Seeking Alpha
biotech
Dynavax
HEPLISAV-B
vaccines
Novavax
NanoFlu
Nerlynx
Puma Biotechnology
breast cancer
Flag link:
5 Small Biotechs Receive Shots in the Arm
5 Small Biotechs Receive Shots in the Arm
TheStreet.com
earnings
Synergy Pharmaceuticals
Omeros
BioDelivery Sciences
Heron Therapeutics
Dynavax
Flag link:
Dynavax's hepatitis B vaccine gets FDA nod on third try, shares up
Dynavax's hepatitis B vaccine gets FDA nod on third try, shares up
Reuters
Dynavax
hepatitis B
vaccines
FDA
HEPLISAV-B
Flag link:
Dynavax shares dip after FDA asks for more time to sort out Heplisav post-marketing plan
Dynavax shares dip after FDA asks for more time to sort out Heplisav post-marketing plan
Endpoints
Dynavax
FDA
Heplisav
vaccines
hepatitis B
Flag link:
Data supports safety of Dynavax hepatitis B vaccine -U.S. FDA panel
Data supports safety of Dynavax hepatitis B vaccine -U.S. FDA panel
Yahoo/Reuters
Dynavax
vaccines
hepatitis B
Heplisav
FDA
advisory panels
Flag link:
Dynavax shares slide as FDA review spotlights a hazy safety issue for Heplisav
Dynavax shares slide as FDA review spotlights a hazy safety issue for Heplisav
Endpoints
Dynavax
FDA
Heplisav
hepatitis B
vaccines
Flag link:
5 Biotech Stocks With Major Catalysts in July
5 Biotech Stocks With Major Catalysts in July
Motley Fool
biotech
AcelRx
Zalviso
Alnylam
Patisiran
Dynavax
HEPLISAV-B
GSK
Benlysta
Puma Biotechnology
neratinib
Flag link:
Dynavax's stock plunges after disappointing FDA response to Hep-B treatment
Dynavax's stock plunges after disappointing FDA response to Hep-B treatment
Marketwatch
Dynavax
hepatitis B
FDA
HEPLISAV-B
Flag link:
What Will Dynavax Do if Heplisav-B Is Rejected?
What Will Dynavax Do if Heplisav-B Is Rejected?
Motley Fool
Dynavax
HEPLISAV-B
vaccines
hepatitis B
FDA
Flag link:
FDA Precedent Suggests Dynavax Hep B Vaccine Faces High Rejection Risk
FDA Precedent Suggests Dynavax Hep B Vaccine Faces High Rejection Risk
TheStreet.com
Dynavax
vaccines
hepatitis B
FDA
Heplisav
Flag link:
5 Small-Cap Biotechs With Big Potential
5 Small-Cap Biotechs With Big Potential
TheStreet.com
biotech
Portola Pharmaceuticals
Progenics
Redhill Biopharma
Dynavax
Amicus Therapeutics
Flag link:
Dynavax, GlaxoSmithKline Battling In Same Industry: Who Will Win?
Dynavax, GlaxoSmithKline Battling In Same Industry: Who Will Win?
Yahoo/Benzinga
Dynavax
GSK
HBV-23
vaccines
hepatitis B
Engerix-B
Flag link:
3 Scorned Biotechs Destined to Rebound
3 Scorned Biotechs Destined to Rebound
TheStreet.com
Merrimack Pharmaceuticals
Relypsa
Amgen
AbbVie
Dynavax
Flag link:
2 Attractive Small Biotech Stocks That Could Become Buyout Targets
2 Attractive Small Biotech Stocks That Could Become Buyout Targets
Seeking Alpha
M&A
biotech
Conatus Pharmaceuticals
Dynavax
Amgen
Celgene
Gilead Sciences
Flag link:
Dynavax & AstraZeneca Alter Agreement for Asthma Product
Dynavax & AstraZeneca Alter Agreement for Asthma Product
Yahoo/Zacks.com
asthma
AstraZeneca
Dynavax
AZD1419
Flag link:
Dynavax Initiates Phase 1/2 Study of TLR-9 Agonist Immunotherapy in B-Cell Lymphoma
Dynavax Initiates Phase 1/2 Study of TLR-9 Agonist Immunotherapy in B-Cell Lymphoma
Yahoo
Dynavax
TLR-9
immuno-oncology
B-cell lymphoma
SD-101
Flag link:

Pages